Shannon Price
Family · Birmingham, ALNPI 1649714007
Payments from drug & device makers
Across 640 payments — averaging $16.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- AbbVie$1K
- Bayer$842
- Amgen$474
- Dexcom, Inc.$407
- plus $4K from 54 others
What the payments were for
- Food & beverage$10,311100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Reltone 200 Mg$115
- GLYCATE$115
- Reltone 400 Mg$115
How this compares
$10,311 in reported general payments places this provider in the 95th percentile of 3,415 family providers in Alabama.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 48 | $45,017 |
| OzempicSemaglutide | 41 | $40,565 |
| MounjaroTirzepatide | 17 | $27,907 |
| JanuviaSitagliptin Phosphate | 20 | $18,585 |
| EliquisApixaban | 14 | $16,982 |
| MyrbetriqMirabegron | 14 | $14,588 |
| LinzessLinaclotide | 11 | $8,387 |
| Synjardy XrEmpagliflozin/Metformin Hcl | 12 | $7,761 |
| Atorvastatin Calcium | 87 | $1,658 |
| Fenofibrate | 22 | $886 |
| Bupropion XlBupropion Hcl | 26 | $878 |
| Levothyroxine Sodium | 72 | $816 |
| Valsartan-HydrochlorothiazideValsartan/Hydrochlorothiazide | 15 | $786 |
| Glipizide ErGlipizide | 25 | $775 |
| Omeprazole | 46 | $741 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Synjardy Xr | $221 | $52,77860 claims |
| Novo NordiskOzempic | $2,208 | $40,56541 claims |
| Lilly USA, LLCMounjaro | $1,014 | $27,90717 claims |
| MerckJanuvia | $15 | $18,58520 claims |
| PfizerEliquis | $314 | $16,98214 claims |
| Astellas Pharma US IncMyrbetriq | $20 | $14,58814 claims |
| AbbVieLinzess | $1,002 | $8,38711 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,415 family providers in Alabama.
Other family in Birmingham
- Kellyn McMahonBirmingham$39K
- Rachel MesserBirmingham$22K
- Juyong JacksonBirmingham$21K
- Abigail McCroryBirmingham$19K
- Danielle BlackardBirmingham$19K
- Leanne PeoplesBirmingham$17K
- Brandie WeidmanBirmingham$13K
- Alison PetersonBirmingham$13K
- Justin WilsonCullman$1.1M
- Leigh Ann ChildressHuntsville$240K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.